GILD vs BIIB stock comparison
Gilead Sciences vs. Biogen · data as of November 13, 2026
Gilead Sciences (GILD) has a market value of about $208.5B, Biogen (BIIB) about $37.5B. Over their latest twelve months Gilead Sciences had revenue of $31.0B and Biogen $10.3B.
On our five checks Gilead Sciences scores higher: 2.8 out of 5 (average) against 1.8 (weak).
By area, the stronger company is Gilead Sciences on track record; Biogen on financial health; Gilead Sciences on shareholder returns.
Gilead Sciences leads on 12 of the compared lines and Biogen on 9.
Side by side
| GILD | BIIB | |
|---|---|---|
| Size and price | ||
| Market cap | $208.5B | $37.5B |
| Share price | $168.08 | $253.40 |
| Score | ||
| Overall score (of 5) | 2.8 | 1.8 |
| Value | 1 | 1 |
| Future growth | 2 | 2 |
| Track record | 4 | 1 |
| Financial health | 3 | 4 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | — | 109.2 |
| Forward P/E | 20.3 | 17.4 |
| Price / free cash flow | 15.1 | 18.1 |
| Price / sales | 6.7 | 3.6 |
| EV / EBITDA | 559.5 | 26.7 |
| PEG | — | — |
| DCF value vs. price | −35% | −33% |
| Business | ||
| Revenue | $31.0B | $10.3B |
| Net income | -$3.9B | $348M |
| Free cash flow | $13.8B | $2.1B |
| Net margin | -12.5% | 3.4% |
| Gross margin (5-yr avg.) | 77.6% | 76.9% |
| ROIC (5-yr avg.) | 12.2% | 9.2% |
| Growth | ||
| Revenue growth (1 yr) | 2.4% | 2.2% |
| Revenue growth (5 yrs, per year) | 3.6% | -6.0% |
| EPS growth (5 yrs, per year) | 132.4% | -18.7% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$19.8B | -$6.1B |
| Dividend yield | 1.95% | None |
| Shareholder yield | 2.9% | 0.0% |
| Analysts | ||
| Upside to average target | +4% | +6% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: GILD TTM to September 30, 2026, BIIB TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Gilead Sciences or Biogen?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Gilead Sciences scores 2.8 out of 5 and Biogen 1.8; the table shows where each one is stronger.
Which grows faster, Gilead Sciences or Biogen?
Over five years Gilead Sciences grew revenue about 3.6% a year and Biogen about -6.0% a year.
Which pays a higher dividend?
Gilead Sciences yields 1.95% and Biogen nothing (no dividend).
Full Gilead Sciences analysis → Full Biogen analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.